Loading
If destroying BTK works when every inhibitor has failed, using it first might stop resistance from ever emerging.
The idea is to use a BTK degrader such as BGB-16673 with a BCL-2 inhibitor such as sonrotoclax as a 12-month fixed-duration frontline regimen for chronic lymphocytic leukaemia, pre-empting the acquired-resistance bottleneck. Degradation removes both kinase and scaffold functions and is not defeated by the C481, T474 or L528 mutations that arise under inhibitor pressure; BGB-16673 works in most heavily pretreated, mutation-bearing patients. The hypothesis is deeper undetectable MRD, longer treatment-free survival and fewer resistance mutations than a covalent BTK inhibitor with venetoclax. The test is a phase 2 of BGB-16673 with sonrotoclax in untreated patients, then a randomised comparison against acalabrutinib-venetoclax; CaDAnCe-304 already tests the degrader in relapse.
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for Acalabrutinib in Chronic lymphocytic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for BCL-2 in Chronic lymphocytic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Acalabrutinib in Chronic lymphocytic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Sonrotoclax, Acalabrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment.
Shares Sonrotoclax, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, BCL-2.
Shares Sonrotoclax, Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, BCL-2.
Shares Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, Acalabrutinib, Chronic lymphocytic leukaemia.
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, BCL-2, Venetoclax.
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, BCL-2.
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.